Please assess the completion status of the following clinical trial:

Trial Title: A Study to Test the Pharmacodynamic, Pharmacokinetic, Safety, and Tolerability of Padsevonil in Healthy Study Participants Receiving Either Ethanol or Cannabidiol

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Participant must be 18 to 55 years of age inclusive, at the time of signing the informed consent~* Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring~* Participant must have previous experience with alcohol consumption and, therefore, must be familiar with the effects and able to tolerate social amounts of alcohol~* Participant has a body weight of at least 50 kg (males) or 45 kg (females) and body mass index (BMI) within the range 18 to 30 kg/m2 (inclusive)~* Participants are male or female:~* A male participant must agree to use contraception as detailed in the protocol during the treatment period and for at least 7 days after the last dose of study treatment and refrain from donating sperm during this period~* A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies:~* Not a woman of childbearing potential (WOCBP) as defined n the protocol OR~* A WOCBP who agrees to follow the contraceptive guidance in the protocol during the Treatment Period and for at least 90 days after the last dose of study treatment~Exclusion Criteria:~* Participant has history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention; or interfering with the interpretation of data~* Participant has a history of chronic alcohol or drug abuse within the previous 6 months or the presence of drug or alcohol dependency at Screening or Day -1 or tests positive for alcohol and/or drugs at Screening or Day -1~* Participant has a known hypersensitivity to any components of the study medication or comparative drugs (and/or an investigational device) as stated in this protocol~* Participant has a history of unexplained syncope or a family history of sudden death due to long QT syndrome~* Participant has lymphoma, leukemia, or any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years~* Participant has past or intended use of over-the-counter or prescription medication including herbal medications within 2 weeks or 5 half-lives prior to dosing~* Participant has used hepatic enzyme-inducing drugs within 2 months prior to dosing~* Participant has alanine transaminase (ALT), aspartate aminotransferase (AST), or alkaline phosphatase (ALP) \>1.0x upper limit of normal (ULN)~* Participant has current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)~* Participant has any clinically relevant electrocardiogram (ECG) finding at the Screening Visit or at Baseline~* Participant has the presence of hepatitis B surface antigen (HBsAg) at Screening or within 3 months prior to dosing~* Participant has a positive hepatitis C antibody test result at Screening or within 3 months prior to starting study intervention~* Participant has a positive human immunodeficiency virus (HIV) antibody test

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Part A: Padsevonil and Ethanol (Type: EXPERIMENTAL): Subjects will be randomized to receive Padsevonil and Ethanol.
- Part A: Padsevonil and Ethanol-Placebo (Type: PLACEBO_COMPARATOR): Subjects will be randomized to receive Padsevonil and Ethanol-Placebo.
- Part A: Ethanol and Ethanol-Placebo (Type: NO_INTERVENTION): Subjects will be randomized to receive Ethanol and Ethanol-Placebo.
- Part A: Ethanol-Placebo and Ethanol (Type: NO_INTERVENTION): Subjects will be randomized to receive Ethanol and Ethanol-Placebo.
- Part B: Padsevonil and Cannabidiol (Type: EXPERIMENTAL): Subjects will be randomized to receive Padsevonil and Cannabidiol.
- Part B: Padsevonil-Placebo and Cannabidiol (Type: PLACEBO_COMPARATOR): Subjects will be randomized to receive Padsevonil-Placebo and Cannabidiol.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval